Immune-related adverse events are associated with efficacy of atezolizumab in patients with advanced NSCLC Presented ByDr Mark Socinski, AdventHealth Cancer Institute, FL, USA TrialPhase 3, IMpower130, IMpower132, IMpower150 ConferenceASCO 2021 12 August, 2021 22:02
